{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:11:20Z","timestamp":1787170280987,"version":"build-2736575974"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["YDZX20243100002003"],"award-info":[{"award-number":["YDZX20243100002003"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23YF1406900"],"award-info":[{"award-number":["23YF1406900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82530088"],"award-info":[{"award-number":["82530088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303943"],"award-info":[{"award-number":["82303943"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473108"],"award-info":[{"award-number":["82473108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20374"],"award-info":[{"award-number":["U21A20374"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.canlet.2026.218285","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:43:11Z","timestamp":1769499791000},"page":"218285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Recent advances in the management of pancreatic neuroendocrine tumors: From diagnosis, treatment to biology"],"prefix":"10.1016","volume":"641","author":[{"given":"Senjie","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-3320","authenticated-orcid":false,"given":"Shunrong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.canlet.2026.218285_bib1","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1158\/1078-0432.CCR-16-0435","article-title":"Translational diagnostics and therapeutics in pancreatic neuroendocrine tumors","volume":"22","author":"Maxwell","year":"2016","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib3","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/SLA.0000000000003478","article-title":"New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis","volume":"274","author":"Zhang","year":"2021","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/gutjnl-2018-317233","article-title":"Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system","volume":"69","author":"Hong","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12022-025-09889-6","article-title":"Molecular subtypes of pancreatic neuroendocrine tumors mutated in MEN1\/DAXX\/ATRX explain biological variability","volume":"36","author":"Avanthay","year":"2025","journal-title":"Endocr. Pathol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000488510","article-title":"Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic neuroendocrine tumours","volume":"107","author":"Basuroy","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40779-024-00535-6","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives","volume":"11","author":"Zhang","year":"2024","journal-title":"Military Med. Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib8","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48323-x","article-title":"C1QA and COMP: plasma-based biomarkers for early diagnosis of pancreatic neuroendocrine tumors","volume":"13","author":"Gorai","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.canlet.2026.218285_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2026.218285_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS Consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124884","article-title":"Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/00365520701561959","article-title":"Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition","volume":"43","author":"Fossmark","year":"2008","journal-title":"Scand. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib16","first-page":"359","article-title":"Critical updates in neuroendocrine tumors: version 9 American joint committee on cancer staging system for gastroenteropancreatic neuroendocrine tumors","volume":"74","author":"Chauhan","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.canlet.2026.218285_bib17","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease","volume":"17","author":"Modlin","year":"2010","journal-title":"Ann. Surg Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ejca.2011.08.012","article-title":"Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments","volume":"48","author":"Korse","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1530\/EC-17-0276","article-title":"Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs","volume":"7","author":"Lv","year":"2018","journal-title":"Endocrine connections"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF03350903","article-title":"Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors","volume":"27","author":"Panzuto","year":"2004","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.canlet.2026.218285_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217502","article-title":"Efficient discovery of robust prognostic biomarkers and signatures in solid tumors","volume":"613","author":"Liu","year":"2025","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.annonc.2019.11.003","article-title":"A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood","volume":"31","author":"\u00d6berg","year":"2020","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/ERC-14-0190","article-title":"A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection","volume":"21","author":"Modlin","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70002","article-title":"NETest\u00ae 2.0-A decade of innovation in neuroendocrine tumor diagnostics","volume":"37","author":"Kidd","year":"2025","journal-title":"J. Neuroendocrinol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000005026","article-title":"Molecular genomic assessment using a blood-based mRNA signature (NETest) is cost-effective and predicts neuroendocrine tumor recurrence with 94% accuracy","volume":"274","author":"Modlin","year":"2021","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib26","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1245\/s10434-021-10021-1","article-title":"Early identification of residual disease after neuroendocrine tumor resection using a liquid biopsy multigenomic mRNA signature (NETest)","volume":"28","author":"Modlin","year":"2021","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2026.218285_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104463","article-title":"Mapping breast cancer therapy with circulating tumor cells: the expert perspective","volume":"81","author":"Gerratana","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/clinchem\/hvad191","article-title":"Breast cancer circulating tumor cells: current clinical applications and future prospects","volume":"70","author":"Cani","year":"2024","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13046-022-02318-0","article-title":"Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer","volume":"41","author":"Raza","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.canlet.2026.218285_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216365","article-title":"Circulating tumor DNA as liquid biopsy in lung cancer: biological characteristics and clinical integration","volume":"577","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218285_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217325","article-title":"Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: a proof of principle study on endocrine resistance profiling","volume":"609","author":"Gerratana","year":"2025","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1200\/JCO.2012.44.2905","article-title":"Circulating tumor cells as prognostic markers in neuroendocrine tumors","volume":"31","author":"Khan","year":"2013","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1158\/1078-0432.CCR-10-1776","article-title":"Circulating tumor cells and EpCAM expression in neuroendocrine tumors","volume":"17","author":"Khan","year":"2011","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ncrna7030038","article-title":"MiRNA expression in neuroendocrine neoplasms of frequent localizations","volume":"7","author":"Korotaeva","year":"2021","journal-title":"Non-coding RNA"},{"issue":"11","key":"10.1016\/j.canlet.2026.218285_bib35","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1245\/s10434-014-3769-4","article-title":"Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States","volume":"21","author":"Gratian","year":"2014","journal-title":"Ann. Surg Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib36","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s11605-021-04946-x","article-title":"Clinical prognosticators of metastatic potential in patients with small pancreatic neuroendocrine tumors","volume":"25","author":"Vega","year":"2021","journal-title":"J. Gastrointest. Surg. : Off. J. Soc. Surg. Aliment. Tract"},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15071955","article-title":"The surgical and therapeutic activities of non-functional pancreatic neuroendocrine tumors at a high-volume institution","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib38","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.asjsur.2022.01.094","article-title":"Impact of tumor grade on pancreatic neuroendocrine tumors","volume":"45","author":"Shyr","year":"2022","journal-title":"Asian J. Surg."},{"key":"10.1016\/j.canlet.2026.218285_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1332387","article-title":"Predicting histologic grades for pancreatic neuroendocrine tumors by radiologic image-based artificial intelligence: a systematic review and meta-analysis","volume":"14","author":"Yan","year":"2024","journal-title":"Front. Oncol."},{"issue":"26","key":"10.1016\/j.canlet.2026.218285_bib40","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.3748\/wjg.v21.i26.8118","article-title":"Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading","volume":"21","author":"Sugimoto","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib41","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2214\/AJR.19.22123","article-title":"CT-Based radiomics score for distinguishing between grade 1 and grade 2 nonfunctioning pancreatic neuroendocrine tumors","volume":"215","author":"Bian","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib42","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s00330-023-10186-1","article-title":"A radiomics-based interpretable model to predict the pathological grade of pancreatic neuroendocrine tumors","volume":"34","author":"Ye","year":"2024","journal-title":"Eur. Radiol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib43","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.acra.2021.05.017","article-title":"Preoperative prediction of G1 and G2\/3 grades in patients with nonfunctional pancreatic neuroendocrine tumors using multimodality imaging","volume":"29","author":"Liu","year":"2022","journal-title":"Acad. Radiol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.diii.2023.08.002","article-title":"Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature","volume":"105","author":"Javed","year":"2024","journal-title":"Diagnostic Inter. Imag."},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib45","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1245\/s10434-024-16064-4","article-title":"Preoperative prediction of lymph node metastases in nonfunctional pancreatic neuroendocrine tumors using a combined CT radiomics-clinical model","volume":"31","author":"Ahmed","year":"2024","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2026.218285_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102269","article-title":"Development and validation of CT-based radiomics deep learning signatures to predict lymph node metastasis in non-functional pancreatic neuroendocrine tumors: a multicohort study","volume":"65","author":"Gu","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib47","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s12967-024-05449-4","article-title":"A novel model for predicting postoperative liver metastasis in R0 resected pancreatic neuroendocrine tumors: integrating computational pathology and deep learning-radiomics","volume":"22","author":"Ma","year":"2024","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.canlet.2026.218285_bib48","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00261-024-04759-x","article-title":"A nomogram to preoperatively predict the aggressiveness of pancreatic neuroendocrine tumors based on CT features and 3D CT radiomic features","volume":"50","author":"Wang","year":"2025","journal-title":"Abdom. Radiol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib49","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2214\/AJR.17.19490","article-title":"CT radiogenomic characterization of the alternative lengthening of telomeres phenotype in pancreatic neuroendocrine tumors","volume":"211","author":"McGovern","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/SLA.0000000000005559","article-title":"Long-term outcomes of parenchyma-sparing and oncologic resections in patients with nonfunctional pancreatic neuroendocrine tumors <3 Cm in a large multicenter cohort","volume":"276","author":"Bolm","year":"2022","journal-title":"Ann. Surg."},{"issue":"11","key":"10.1016\/j.canlet.2026.218285_bib51","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s11605-012-2002-7","article-title":"Parenchyma-sparing resections for pancreatic neuroendocrine tumors","volume":"16","author":"Cherif","year":"2012","journal-title":"J. Gastrointest. Surg. : Off. J. Soc. Surg. Aliment. Tract"},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pan.2019.12.007","article-title":"Propensity score-matched analysis of clinical outcome after enucleation versus regular pancreatectomy in patients with small non-functional pancreatic neuroendocrine tumors","volume":"20","author":"Weilin","year":"2020","journal-title":"Pancreatology : Off. J. Int. Assoc. Pancreatol. (IAP) [et al]"},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11605-017-3365-6","article-title":"Pancreatic neuroendocrine tumors (panNETs): analysis of overall survival of nonsurgical management versus surgical resection","volume":"21","author":"Finkelstein","year":"2017","journal-title":"J. Gastrointest. Surg. : Off. J. Soc. Surg. Aliment. Tract"},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib54","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.surg.2018.08.015","article-title":"Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: results from the US neuroendocrine tumor study group","volume":"165","author":"Zhang","year":"2019","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/bjs.6051","article-title":"Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas","volume":"95","author":"Fischer","year":"2008","journal-title":"Br. J. Surg."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib56","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.pan.2016.07.006","article-title":"Short- and long-term outcomes after enucleation of pancreatic tumors: an evidence-based assessment","volume":"16","author":"Zhou","year":"2016","journal-title":"Pancreatology : Off. J. Int. Assoc. Pancreatol. (IAP) [et al]"},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jjco\/hyaa246","article-title":"Comparison of clinical outcomes between enucleation and regular pancreatectomy in patients with non-functional pancreatic neuroendocrine tumors: a retrospective multicenter and propensity score-matched study","volume":"51","author":"Yang","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib58","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11605-012-1971-x","article-title":"Risk factors for postoperative pancreatic fistulization subsequent to enucleation","volume":"16","author":"Brient","year":"2012","journal-title":"J. Gastrointest. Surg. : Off. J. Soc. Surg. Aliment. Tract"},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib59","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1097\/JS9.0000000000002511","article-title":"Evaluation of tumor pseudocapsule using computed tomography-based radiomics in pancreatic neuroendocrine tumors to predict prognosis and guide surgical strategy: a cohort study","volume":"111","author":"Wang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.canlet.2026.218285_bib60","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2025.4054","article-title":"Minimally invasive vs open left pancreatectomy for resectable pancreatic cancer: long-term results of the randomized DIPLOMA trial","author":"Bruna","year":"2025","journal-title":"JAMA Surg."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib61","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/SLA.0000000000006681","article-title":"Effect of laparoscopic versus open distal pancreatectomy on recurrence-free survival in patients with left-sided pancreatic cancer: a randomized controlled trial","volume":"282","author":"Liu","year":"2025","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2468-1253(19)30004-4","article-title":"Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2\/3 trial","volume":"4","author":"van Hilst","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib63","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jso.25026","article-title":"Minimally invasive versus open pancreatic enucleation. Systematic review and meta-analysis of surgical outcomes","volume":"117","author":"Guerra","year":"2018","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/SLA.0000000000002979","article-title":"Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial","volume":"269","author":"de Rooij","year":"2019","journal-title":"Ann. Surg."},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib65","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/bjs.11554","article-title":"Comparison of the duration of hospital stay after laparoscopic or open distal pancreatectomy: randomized controlled trial","volume":"107","author":"Bj\u00f6rnsson","year":"2020","journal-title":"Br. J. Surg."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/SLA.0000000000001660","article-title":"Minimally invasive versus open pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and registry studies","volume":"264","author":"de Rooij","year":"2016","journal-title":"Ann. Surg."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2468-1253(21)00054-6","article-title":"Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Wang","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00423-025-03662-3","article-title":"Comparison of outcomes of laparoscopic vs. robotic surgical resection of pancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"410","author":"Singh","year":"2025","journal-title":"Langenbecks Arch. Surg."},{"issue":"8","key":"10.1016\/j.canlet.2026.218285_bib69","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1245\/s10434-024-15249-1","article-title":"Impact of regional metastasis on survival for patients with nonfunctional pancreatic neuroendocrine tumors: a systematic review","volume":"31","author":"Clarke","year":"2024","journal-title":"Ann. Surg Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12893-022-01595-y","article-title":"Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Surg."},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib71","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1007\/s11605-016-3243-7","article-title":"Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas","volume":"20","author":"Conrad","year":"2016","journal-title":"J. Gastrointest. Surg. : Off. J. Soc. Surg. Aliment. Tract"},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib72","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MPA.0000000000001493","article-title":"Prognostic value and clinical predictors of lymph node metastases in pancreatic neuroendocrine tumors","volume":"49","author":"Zhang","year":"2020","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.canlet.2026.218285_bib73","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00595-017-1485-y","article-title":"Significance of lymph node metastasis in pancreatic neuroendocrine tumor","volume":"47","author":"Taki","year":"2017","journal-title":"Surg. Today"},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib74","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib75","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/jso.25689","article-title":"Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: a multi-institutional analysis","volume":"120","author":"Wu","year":"2019","journal-title":"J. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218285_bib76","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1245\/s10434-019-07506-5","article-title":"Outcomes of lymph node dissection for non-metastatic pancreatic neuroendocrine tumors: a propensity score-weighted analysis of the national cancer database","volume":"26","author":"Mao","year":"2019","journal-title":"Ann. Surg Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11605-020-04521-w","article-title":"Role of lymph node resection and histopathological evaluation in accurate staging of nonfunctional pancreatic neuroendocrine tumors: how many are enough?","volume":"25","author":"Ding","year":"2021","journal-title":"J. Gastrointest. Surg. : Off. J. Soc. Surg. Aliment. Tract"},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J. Neuroendocrinol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218285_bib79","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13318","article-title":"European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J. Neuroendocrinol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218285_bib80","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jamaoncol.2018.2428","article-title":"Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Singh","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218285_bib81","article-title":"A cross-species transcriptomic analysis reveals a novel 2-dimensional classification system explaining the invasiveness heterogeneity of pancreatic neuroendocrine tumor","author":"Hong","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000488394","article-title":"Follow-Up for resected gastroenteropancreatic neuroendocrine tumours: a practice survey of the commonwealth neuroendocrine tumour collaboration (CommNETS) and the north American neuroendocrine tumor society (NANETS)","volume":"107","author":"Chan","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib83","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djs208","article-title":"TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study","volume":"104","author":"Rindi","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib84","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.hbpd.2018.03.002","article-title":"Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems","volume":"17","author":"Benetatos","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int. : HBPD INT"},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib85","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.hpb.2017.08.034","article-title":"Prognosis of sporadic resected small (\u22642 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study","volume":"20","author":"Sallinen","year":"2018","journal-title":"HPB : Off. J. Int. Hepato Pancreato Biliary Assoc."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib86","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000495774","article-title":"Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where?","volume":"108","author":"Marchegiani","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib87","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1159\/000514047","article-title":"Meta-analysis of prognostic factors for recurrence of resected well-differentiated pancreatic neuroendocrine tumors","volume":"111","author":"Li","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib88","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1245\/s10434-016-5663-8","article-title":"Pancreatic duct involvement in well-differentiated neuroendocrine tumors is an independent poor prognostic factor","volume":"24","author":"Nanno","year":"2017","journal-title":"Ann. Surg Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12022-022-09745-x","article-title":"Infiltrative growth predicts the risk of recurrence after surgery in well-differentiated non-functioning pancreatic neuroendocrine tumors","volume":"34","author":"Schiavo Lena","year":"2023","journal-title":"Endocr. Pathol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib90","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/SLA.0000000000003579","article-title":"Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors","volume":"274","author":"Pulvirenti","year":"2021","journal-title":"Ann. Surg."},{"key":"10.1016\/j.canlet.2026.218285_bib91","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijsu.2019.12.034","article-title":"Novel scoring system for recurrence risk classification of surgically resected G1\/2 pancreatic neuroendocrine tumors - retrospective cohort study","volume":"74","author":"Zou","year":"2020","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.canlet.2026.218285_bib92","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.canlet.2017.10.036","article-title":"Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor","volume":"412","author":"Gao","year":"2018","journal-title":"Cancer Lett."},{"issue":"6021","key":"10.1016\/j.canlet.2026.218285_bib93","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science (New York, NY)"},{"issue":"7643","key":"10.1016\/j.canlet.2026.218285_bib94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib95","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.10.020","article-title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors","volume":"146","author":"Marinoni","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib96","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","article-title":"Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors","volume":"23","author":"Singhi","year":"2017","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib97","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","article-title":"Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size","volume":"71","author":"Hackeng","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12022-025-09848-1","article-title":"Clinical relevance of ATRX\/DAXX gene mutations and ALT in functioning pancreatic neuroendocrine tumors","volume":"36","author":"van","year":"2025","journal-title":"Endocr. Pathol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib99","doi-asserted-by":"crossref","first-page":"e949","DOI":"10.1097\/SLA.0000000000003624","article-title":"Immunohistochemically detected expression of ATRX, TSC2, and PTEN predicts clinical outcomes in patients with grade 1 and 2 pancreatic neuroendocrine tumors","volume":"274","author":"Uemura","year":"2021","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib100","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/2159-8290.CD-15-0068","article-title":"A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics","volume":"5","author":"Sadanandam","year":"2015","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib101","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/SLA.0000000000003022","article-title":"Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases","volume":"271","author":"Pea","year":"2020","journal-title":"Ann. Surg."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109817","article-title":"Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms","volume":"37","author":"Yang","year":"2021","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.03.016","article-title":"Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups","volume":"43","author":"Ji","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218285_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217821","article-title":"Role of artificial intelligence in cancer drug discovery and development","volume":"627","author":"Sarvepalli","year":"2025","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.canlet.2026.218285_bib105","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2026.218285_bib106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib107","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer."},{"issue":"3\u20134","key":"10.1016\/j.canlet.2026.218285_bib108","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000439086","article-title":"Streptozocin and 5-Fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity","volume":"103","author":"Clewemar Antonodimitrakis","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.canlet.2026.218285_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102899","article-title":"The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms - a systematic review","volume":"134","author":"Arrivi","year":"2025","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000225389","article-title":"Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors","volume":"90","author":"Maire","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib111","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib112","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib113","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.6004\/jnccn.2021.7017","article-title":"Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms","volume":"20","author":"Al-Toubah","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw. : J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218285_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101667","article-title":"S-1\/temozolomide versus S-1\/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): a randomised, open-label, multicentre phase 2 trial","volume":"54","author":"Chi","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"24","key":"10.1016\/j.canlet.2026.218285_bib117","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib118","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2006.07.4807","article-title":"Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide","volume":"25","author":"Chinot","year":"2007","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.canlet.2026.218285_bib119","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2006.06.3891","article-title":"Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study","volume":"24","author":"Brandes","year":"2006","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib120","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2026.218285_bib121","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib122","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/curroncol30020106","article-title":"Prospective evaluation of MGMT-promoter methylation status and correlations with outcomes to temozolomide-based chemotherapy in well-differentiated neuroendocrine tumors","volume":"30","author":"Brighi","year":"2023","journal-title":"Curr. Oncol."},{"issue":"35","key":"10.1016\/j.canlet.2026.218285_bib123","article-title":"MEN1 deficiency-driven activation of the \u03b2-Catenin-MGMT axis promotes pancreatic neuroendocrine tumor growth and confers temozolomide resistance","volume":"11","author":"Xu","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"9","key":"10.1016\/j.canlet.2026.218285_bib124","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1530\/ERC-16-0147","article-title":"Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","volume":"23","author":"Cives","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib125","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/MPA.0000000000000842","article-title":"O6-Methylguanine DNA methyltransferase status does not predict response or resistance to alkylating agents in well-differentiated pancreatic neuroendocrine tumors","volume":"46","author":"Raj","year":"2017","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib126","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.canlet.2026.218285_bib127","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-14-0360","article-title":"Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors","volume":"22","author":"Cives","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2026.218285_bib129","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10446","key":"10.1016\/j.canlet.2026.218285_bib131","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib132","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1007\/s00259-025-07235-w","article-title":"Safety and efficacy of re-treatment with [(177)Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience","volume":"52","author":"Kashyap","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"11","key":"10.1016\/j.canlet.2026.218285_bib133","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","article-title":"Surgical feasibility, determinants, and overall efficacy of neoadjuvant (177)Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors","volume":"62","author":"Parghane","year":"2021","journal-title":"J. Nucl. Med. : Off. Pub. Soc. Nuclear Med."},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib134","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening Horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib135","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1535-7163.MCT-18-1103","article-title":"Preclinical investigation of (212)Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model","volume":"18","author":"Stallons","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib136","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218285_bib137","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211042689","article-title":"Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)","volume":"13","author":"Xu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218285_bib138","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218285_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115398","article-title":"Surufatinib in advanced neuroendocrine tumours: final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)","volume":"222","author":"Xu","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib140","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib141","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"32","key":"10.1016\/j.canlet.2026.218285_bib142","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J. Clin. Oncol. : Off. J. Ame. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib143","first-page":"713","article-title":"A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours","volume":"36","author":"Fazio","year":"2016","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib144","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1158\/1535-7163.MCT-17-1204","article-title":"A patient-derived xenograft model of pancreatic neuroendocrine tumors identifies sapanisertib as a possible new treatment for everolimus-resistant tumors","volume":"17","author":"Chamberlain","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib145","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.04.010","article-title":"Metformin use is associated with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and\/or somatostatin analogues","volume":"155","author":"Pusceddu","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.canlet.2026.218285_bib146","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082143","article-title":"Metformin and everolimus: a promising combination for neuroendocrine tumors treatment","volume":"12","author":"Vitali","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib147","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2026.218285_bib148","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3389\/fonc.2020.01047","article-title":"Lanreotide induces cytokine modulation in intestinal neuroendocrine tumors and overcomes resistance to everolimus","volume":"10","author":"Sciammarella","year":"2020","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib149","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib150","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/annonc\/mdx078","article-title":"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"28","author":"Kulke","year":"2017","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2026.218285_bib151","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.canlet.2026.218285_bib152","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1158\/1078-0432.CCR-11-3264","article-title":"Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4\/cdk6","volume":"18","author":"Tang","year":"2012","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2026.218285_bib153","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0033","article-title":"The PALBONET trial: a phase II study of palbociclib in metastatic grade 1 and 2 pancreatic neuroendocrine tumors (GETNE-1407)","volume":"25","author":"Grande","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218285_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.canlet.2026.218285_bib155","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/cncr.32883","article-title":"Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","volume":"126","author":"Mehnert","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2026.218285_bib156","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2026.218285_bib157","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","article-title":"Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial","volume":"26","author":"Lu","year":"2020","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib158","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011760","article-title":"Phase II basket trial of dual Anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort","volume":"13","author":"Patel","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib159","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000517688","article-title":"Analysis of immune landscape in pancreatic and ileal neuroendocrine tumours demonstrates an immune cold tumour microenvironment","volume":"112","author":"Tanno","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib160","article-title":"The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib161","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib162","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/jjco\/hyaa021","article-title":"Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data","volume":"50","author":"Wallis","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218285_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218285_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - exploring the \"space\"","volume":"622","author":"Br\u00e4utigam","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218285_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113539","article-title":"Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: an open-label, single-arm, multi-cohort phase II trial","volume":"199","author":"Zhang","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib166","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-22-1552","article-title":"A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms","volume":"29","author":"Owen","year":"2023","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib167","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2967\/jnumed.123.265391","article-title":"Addition of peptide receptor radiotherapy to immune checkpoint inhibition therapy improves outcomes in neuroendocrine tumors","volume":"64","author":"Esfahani","year":"2023","journal-title":"J. Nucl. Med. : Off. Pub. Soc. Nuclear Med."},{"key":"10.1016\/j.canlet.2026.218285_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218076","article-title":"Tumor microenvironment and macroenvironment: a new perspective on holistic oncology","volume":"634","author":"Chen","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218285_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217918","article-title":"Circulating cytokine profiling and clustering identify biomarker predicting efficacy of ICI in combination with chemotherapy","volume":"631","author":"Xu","year":"2025","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib170","first-page":"596","article-title":"Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma","volume":"71","author":"Kaku","year":"1980","journal-title":"Gan"},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib171","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0016-5085(91)90004-5","article-title":"Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth","volume":"101","author":"Evers","year":"1991","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib172","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s13577-022-00696-3","article-title":"Establishment and characterization of the third non-functional human pancreatic neuroendocrine tumor cell line","volume":"35","author":"Lou","year":"2022","journal-title":"Hum. Cell"},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib173","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/JME-14-0304","article-title":"Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1","volume":"54","author":"Vandamme","year":"2015","journal-title":"J. Mol. Endocrinol."},{"issue":"7\u20138","key":"10.1016\/j.canlet.2026.218285_bib174","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cancergen.2015.04.002","article-title":"Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines","volume":"208","author":"Boora","year":"2015","journal-title":"Cancer Genet."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib175","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/1541-7786.MCR-17-0163","article-title":"Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model","volume":"16","author":"Benten","year":"2018","journal-title":"Mol. Cancer Res. : MCR"},{"issue":"6","key":"10.1016\/j.canlet.2026.218285_bib176","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s13402-022-00727-z","article-title":"Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy","volume":"45","author":"Viol","year":"2022","journal-title":"Cell. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib177","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12022-016-9429-4","article-title":"Establishment and characterization of a human neuroendocrine tumor xenograft","volume":"27","author":"Yang","year":"2016","journal-title":"Endocr. Pathol."},{"issue":"16","key":"10.1016\/j.canlet.2026.218285_bib178","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1073\/pnas.1600007113","article-title":"Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors","volume":"113","author":"Krampitz","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib179","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s13577-024-01107-5","article-title":"Comparison among different preclinical models derived from the same patient with a non-functional pancreatic neuroendocrine tumor","volume":"37","author":"Wang","year":"2024","journal-title":"Hum. Cell"},{"key":"10.1016\/j.canlet.2026.218285_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217968","article-title":"Organoids in the research of pancreatic neoplasms: cultivation, applications, and limitations","volume":"632","author":"Du","year":"2025","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.canlet.2026.218285_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.10.023","article-title":"An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping","volume":"183","author":"Kawasaki","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib182","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/s41467-022-29857-6","article-title":"Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity","volume":"13","author":"Shi","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib183","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41568-018-0104-6","article-title":"Modelling cancer in microfluidic human organs-on-chips","volume":"19","author":"Sontheimer-Phelps","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.canlet.2026.218285_bib184","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/cac2.12224","article-title":"Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy","volume":"41","author":"Qu","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2026.218285_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217122","article-title":"Establishment of advanced tumor organoids with emerging innovative technologies","volume":"598","author":"Mao","year":"2024","journal-title":"Cancer Lett."},{"issue":"6015","key":"10.1016\/j.canlet.2026.218285_bib186","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/315115a0","article-title":"Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin\/simian virus 40 oncogenes","volume":"315","author":"Hanahan","year":"1985","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2026.218285_bib187","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0896-6273(88)90110-9","article-title":"Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic alpha cells","volume":"1","author":"Efrat","year":"1988","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib188","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.canlet.2026.218285_bib189","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.canlet.2026.218285_bib190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12020-023-03299-6","article-title":"Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges","volume":"80","author":"Wang","year":"2023","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib191","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1073\/pnas.98.3.1118","article-title":"A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors","volume":"98","author":"Crabtree","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.canlet.2026.218285_bib192","first-page":"4836","article-title":"Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice","volume":"63","author":"Bertolino","year":"2003","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.canlet.2026.218285_bib193","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1128\/MCB.23.17.6075-6085.2003","article-title":"Of mice and MEN1: Insulinomas in a conditional mouse knockout","volume":"23","author":"Crabtree","year":"2003","journal-title":"Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218285_bib194","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1210\/en.2009-1251","article-title":"Multiple endocrine neoplasia type 1 deletion in pancreatic alpha-cells leads to development of insulinomas in mice","volume":"151","author":"Shen","year":"2010","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib195","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41418-019-0355-0","article-title":"Two well-differentiated pancreatic neuroendocrine tumor mouse models","volume":"27","author":"Wong","year":"2020","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.canlet.2026.218285_bib196","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0092-8674(02)00738-9","article-title":"Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression","volume":"109","author":"Pelengaris","year":"2002","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.canlet.2026.218285_bib197","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1172\/JCI35237","article-title":"Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation","volume":"118","author":"Alliouachene","year":"2008","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.canlet.2026.218285_bib198","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/ERC-16-0443","article-title":"Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis","volume":"24","author":"Saloustros","year":"2017","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:07:50Z","timestamp":1777550870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":198,"alternative-id":["S0304383526000480"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218285","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the management of pancreatic neuroendocrine tumors: From diagnosis, treatment to biology","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218285"}}